Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry.

Viktorin-Baier, Pascal; Putora, Paul M.; Schmid, Hans-Peter; Plasswilm, Ludwig; Schwab, Christoph; Thoeni, Armin; Hochreiter, Werner; Prikler, Ladislav; Suter, Stefan; Stucki, Patrick; Müntener, Michael; Blick, Nadja; Schiefer, Hans; Güsewell, Sabine; Zürn, Karin; Engeler, Daniel (2020). Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry. BJU international, 125(6), pp. 827-835. Wiley 10.1111/bju.15003

[img] Text
bju.15003.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (771kB) | Request a copy

OBJECTIVE

To evaluate the long-term oncological, functional and toxicity outcomes of low-dose-rate brachytherapy (LDR-BT) in relation to risk factors and radiation dose in a prospective multicentre cohort.

PATIENTS AND METHODS

Data of patients from 12 Swiss centres undergoing LDR-BT from September 2004 to March 2018 were prospectively collected. Patients with a follow-up of ≥3 months were analysed. Functional and oncological outcomes were assessed at ~6 weeks, 6 and 12 months after implantation and annually thereafter. LDR-BT was performed with 125 I seeds. Dosimetry was done 6 weeks after implantation based on the European Society for Radiotherapy and Oncology recommendations. The Kaplan-Meier method was used for biochemical recurrence-free survival (BRFS). A prostate-specific antigen (PSA) rise above the PSA nadir + 2 was defined as biochemical failure. Functional outcomes were assessed by urodynamic measurement parameters and questionnaires.

RESULTS

Of 1580 patients in the database, 1291 (81.7%) were evaluable for therapy outcome. The median (range) follow-up was 37.1 (3.0-141.6) months. Better BRFS was found for Gleason score ≤3+4 (P = 0.03, log-rank test) and initial PSA level of <10 ng/mL (P < 0.001). D'Amico Risk groups were significantly associated with BRFS (P < 0.001), with a hazard ratio of 2.38 for intermediate- and high-risk patients vs low-risk patients. The radiation dose covering 90% of the prostate volume (D90) after 6 weeks was significantly lower in patients with recurrence. Functional outcomes returned close to baseline levels after 2-3 years. A major limitation of these findings is a substantial loss to follow-up.

CONCLUSION

Our results are in line with other studies showing that LDR-BT is associated with good oncological outcomes together with good functional results.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Putora, Paul Martin and Plasswilm, Ludwig

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1464-410X

Publisher:

Wiley

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

30 Nov 2020 15:47

Last Modified:

30 Nov 2020 15:56

Publisher DOI:

10.1111/bju.15003

PubMed ID:

31965694

Uncontrolled Keywords:

#PCSM #ProstateCancer biochemical recurrence low-dose-rate brachytherapy morbidities toxicity

BORIS DOI:

10.7892/boris.147623

URI:

https://boris.unibe.ch/id/eprint/147623

Actions (login required)

Edit item Edit item
Provide Feedback